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Sttnary 
Transplantation of HLA mismatched hematopoietic stem cells in patients with severe combined 
immunoddiciency (SCID) can result in a selective engraftment of T cells of donor origin with 
complete immunologic reconstitution and in vivo tolerance. The latter may occur in the absence 
of clonal deletion of donor T lymphocytes able to recognize the host HLA antigens. The activity 
of these host-reactive T  cells is suppressed in vivo, since no graft-vs.-host disease is observed 
in these human chimeras.  Here it is shown that the CD4 + host-reactive T cell clones isolated 
from a SCID patient transplanted with fetal liver stem cells produce unusually high quantities 
ofinterleukin 10 (IL-10) and very low amounts of IL-2 after antigen-specific stimulation in vitro. 
The specific proliferative responses of the host-reactive T cell clones were considerably enhanced 
in the presence of neutralizing concentrations of an anti-IL- 10 monodonal antibody, suggesting 
that high levels of endogenous IL-10  suppress the activity of these cells. These in vitro data 
correlate with observations made in vivo. Semi-quantitative polymerase chain reaction analysis 
carried out on freshly isolated peripheral blood mononuclear cells (PBMC) of the patient indicated 
that the levels of IL-10 messenger KNA (mRNA) expression were strongly enhanced, whereas 
IL-2 mKNA expression was much lower than that in PBMC of healthy donors. In vivo IL-10 
mRNA expression was not only high in the T cells, but also in the non-T cell fraction, indicating 
that host cells also contributed to the high levels of IL-10 in vivo. Patient-derived monocytes 
were found to be major IL-10 producers. Although no circulating IL-10 could be detected, freshly 
isolated monocytes of the patient showed a reduced expression of class II HLA antigens. However, 
their capacity to stimulate T cells of normal donors in primary mixed lymphocyte cultures was 
within the normal range. Interestingly, similar high in vivo IL-10 mKNA expressions in the 
T  and non-T cell compartment were also observed in three SCID patients transplanted with 
fetal liver stem cells and in four SCID patients transplanted with T cell-depleted haploidentical 
bone marrow stem cells. Taken together, these data indicate that high endogenous IL-10 production 
is a general phenomenon in SCID patients in whom allogeneic stem cell transplantation results 
in immunologic  reconstitution and induction of tolerance. Both donor T cells and host accessory 
cells contribute to these high levels of IL-10, which would suppress the activity of host-reactive 
T  cell in vivo. 
G 
VHD remains the major clinical problem after allogeneic 
hematopoietic stem cell transplantation (1-3). Removal 
of donor T  lymphocytes, which are the principal effectors 
in antihost reactivity,  by T cell depletion of the graft or T 
cell inactivation by administration of immunosupFressive drugs 
can only limit, but not avoid, GVHD. Therefore, allogeneic 
stem cell transplantations generally result in different grades 
of GVHD. On the other hand, there are situations in which 
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between  hosts  and  donors.  Examples  are  SCID  patients 
who have been cured after HLA mismatched bone marrow 
(BMT) 1 or fetal liver (FLT) stern cells transplantations  (4-8). 
In these children,  a split chimerism, with T/NK ceils of donor 
origin and B cells/monocytes of host origin is often observed, 
which, however, does not prevent the establishment of normal 
immune responses in vivo and in vitro (6-10). Furthermore, 
complete tolerance is achieved between donor- and host-derived 
calls.  However,  in  some  of these  patients,  donor-derived 
CD8 + and CD4 + T cells specific for class I and II HLA Ags 
of the host have been detected at high frequencies in vitro 
(11, 12).  This indicates  that  tolerance is not due to clonal 
deletion of host-reactive T cells, but suggests that peripheral 
mechanisms are responsible for the unresponsiveness to the 
host ceils  in vivo. 
Studies in  mouse chimeras  suggested that  self-  or allo- 
antigen-specific T  cells may escape donal deletion and be- 
come anergic (13). Although it is not dear how anergic cells 
are regulated, it has been hypothesized that lymphokines may 
induce and/or maintain this nondeletional type of tolerance 
(14). It has been shown in animal models, that anergic cells 
have an altered regulation of the IL-2 pathway in response 
to antigens, which may account for their functional inactiva- 
tion  (15). 
Recently, IL-10 has been identified as a critical cytokine 
suppressing multiple activities of the immune response (16, 
17). Human IL-10 is produced by different cell types, including 
T  cells, monocytes, and B cells, after activation (18,  19). In 
vitro studies have shown that IL-10 prevents Ag-specific T 
cell proliferation  indirectly by reducing  the Ag-presenting 
capacity of monocytes that  is associated with downregula- 
tion ofchss II HLA expression (20). In addition, IL-10 directly 
suppresses T  cell proliferation by specific inhibition of IL-2 
production by T  cells  (21).  Similarly,  IL-10 has potent in- 
hibitory effects on alloantigen-induced proliferative and cyto- 
toxic T cell responses (22). IL-10 also inhibits cytokine syn- 
thesis by activated monocytes, and it downregulates its own 
production, suggesting that it can affect immune responses 
via an autoregulatory feedback mechanism (18). Overall, these 
biological activities indicate that IL-10 is a potent negative 
regulator of immunoproliferative and inflammatory responses, 
including  aHoreactivity. 
In this study, we describe that the CD4 + host-reactive T 
cell clones isolated from a SCID human chimera produce very 
low levels of IL-2 and unusually high amounts of IL-10, which 
partially inhibit  their proliferation  in vitro.  Moreover,  the 
amounts of IL-10 messenger RNA (mRNA) in the PBMC 
of the patient, as well as in the PBMC of seven other patients 
tested,  were considerably higher  than  those in  PBMC of 
normal  donors.  Interestingly,  the  highest  levels  of IL-10 
mRNA were expressed in the non-T cell subset. Taken to- 
1 Abbreviations used in thispaper: FIT, fetal liver stem cell transplantation; 
BMT, bone  marm~ stem  cell  tramplantation; KBV-I/2L,  RBV-tramfomled- 
lymphoblastoid  cell line; HPRT, hypmanthine phosphotibosyltransferase; 
MFI, mean fluorescence  intensity; mRNA, messenger RNA. 
gether, these data indicate that endogenous IL-IO, produced 
by donor and particularly host cells, may play a key role in 
maintaining in vivo tolerance after allogeneic stem cell trans- 
plantation by suppressing the antihost  reactivity of donor- 
derived T  cells. 
Materiah  and Methods 
Patients.  The clinical history and follow-up of patient RV have 
been described in detail previously (12). Briefly, the patient  was 
diagnosed to suffer  from SCLD, with no T cells but normal numbers 
of monocytes and B cells. He received 7 FLT 6 yr ago obtained 
from multiple  HLA mismatched donors. These transplantations 
resulted in a stable engraftment  of T and NK cells of one donor, 
whereas B cells and monocytes remained of host origin. The per- 
centages of CD2 § and CD3 § cells have always been in the normal 
range, but the CD4/CD8 ratio was constantly inverted (0.6). In 
addition,  a high proportion  (30%)  of the CD3 § T  cells were 
TCK-v/6 §  The percentage of NK cells remained low (<4%). 
The patient is healthy, but there is no complete restoration of Ig 
production  which requires Ig treatment  every 3 wk. 
Patients SP, MJ, and TD were also treated with FLT. Patients 
SP and MJ were affected with SCID and they were transplanted 
17 and 11 yr ago, respectively. Their clinical history and immuno- 
logical findings have already been described (8, 23). Patient TD 
suffered from bare lymphocyte syndrome, a genetically transmitted 
form of SCID, clue to a lack of expression of HLA antigens. His 
clinical history has been previously reported  (24). He received a 
transplant 5 yr ago in utero at 28 wk of gest~tional age. The FLT 
patients did not receive any immunosuppressive treatment  before 
or after transplantation. 
NJL, DE, TJ, and VR are SCID patients transplanted with pa- 
rental haploidentical BMT, previously depleted of T cells by agglu- 
tination with soybean agglutinin  and E-rosette formation.  Before 
the transplant, they were conditioned with antithymocyte globulin, 
and cyclophosphamide. NJL and VR received transplants 4 and 5 
yr ago, respectively, and they did not receive any immunosuppres- 
sive therapy in the past 3 yr. DE and TJ were transplanted 5 and 
8 mo ago, respectively, and they are still under treatment with cy- 
closporin and steroids. 
Establishment  of T  Cell  Clones.  CD4 + host-reactive  T  cell 
clones were obtained from the PBMC of patient RV after two sub- 
sequent activations with the host's EBV-transformed  lymphoblastoid 
cell line (EBV-I.CL), in the presence of ID2,  as described (12). 
CD4 + a11oreactive T cell clones were obtained from the PBMC 
of the patient and from a normal donor after the same procedure, 
using HLA mismatched EBV-LCL as stimulator ceils. The cloning 
was performed by limiting dilution at 0.3 cells/well in the presence 
of a feeder cell mixture,  PHA and IL-2 (12). T cell clones were 
screened for Ag specificity by testing  proliferation  and  IFN-v 
production in response to the host-derived or allogeneic EBV-I.CL, 
as previously described (12). T cell clones were maintained in cul- 
ture by weekly restimulation with the feeder ceil mixture and PHA. 
Between stimulations with feeder ceils, the T cell clones were ex- 
panded with IL-2. 
Reagents.  Purified recombinant human Ibl0 was provided by 
Schering-Plough Research (Bloomfield, NJ). The blocking anti- 
IL-10 mAb 19F1 has been described (25). The anti-IL-2 receptor 
mAb B-B10 and anti-CD3 mAb SPV-T3 were previously described 
(26, 27). FITC or PE-conjugated, anti-CD3 (anti-Leu4), anti-CD14 
(anti-LeuM3), anti-CD16  (anti-Leulla),  anti-CD19  (anti-Leu12), 
anti-CD20  (anti-Leu16), anti-CD56  (anti-Leu19), anti-HI.A-DR 
(anti-HLA-DR)  mAbs and control mAbs of the appropriate iso- 
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View, CA).  Magnetic beads (Dynabeads M-450; Dynal,  Oslo, 
Norway) were used at a bead to cell ratio of 5:1 to obtain purified 
normal donor T  cells negatively depleted of CD14 §  CD16*, 
CD19 +, and CD56 + cells, as described by the supplier. 
Proliferation Assays.  T  cell clones (2  x  104  cells/well) or 
purified T  cells (10  s cells/weil) were stimulated with purified 
monocytes (4  x  104 cells/well) in 200-/~1 in flat-bottomed 96-well 
plates. The monocytes of patient RV and of normal donors 1 and 
2 were isolated from  PBMC  by sorting  CD14  + cells (purity 
>99%).  For another series of experiments, monocytes of normal 
donors were isolated from PBMC by density centrifugation in a 
blood component separator, followed  by centrifugal  elutriation (18). 
These monocyte preparations, which were 95% pure, had either 
the HLA-DR phenotype of the host, or that of the allogeneic  EBV- 
LCL that had been used to generate the T cell clones. For measure- 
ment of the proliferation of T cell clones, cells were cultured for 
72 h at 37~  in 5% COz, and subsequently pulsed with [3H]TdR 
for 6 h, and harvested as described previously (12). Proliferation 
of purified T cells was measured after incubation period of 4 d, 
followed by [3H]TdR incorporation for 12 h. All tests were car- 
ried out in triplicate. 
Primers and Probes.  The following primers were used for PCR 
analysis: hypoxanthine phosphoribosyltransferase (HPRT)  sense 
primer 5'-TATC~ACAGGACTGAACGTCTTGC-Y; HPRT an- 
tisense primer  5'-GACACAAACATGATTCAAATCCCTGA-3'; 
IL-2 sense 5'-AAGAATCCCAAACTCACCAGGATC~-3';  IL-2  an- 
tisense 5'-CCCTTTAGTTCCAGAACTATTACGT-3';  IL-10  sense 
5'-ATGCCCCAA~AGAACCAAGACCCA-Y; Ibl0 antisense 
5'-TCTCAAGGGGCTGGGTCAGCTATCCCA-Y (28); IFN-~/ 
sense  5'-ATGAAATATACAAGTTATATCTTGGCTTT-3'; and 
IFN-~/antisense 5'-GATCK2TCTTCGACCTCGAAACAGCAT-3'. 
The following oligonucleotides were used for Southern analysis 
of PCK products: HPRT 5'-GTCCCCTGTTGACTGGTCATT- 
ACAAT-3'; Ib2 5'-CATC~CCAAGAAGGCCACAGAACTGAA- 
ACA-3';  IL-10 5'-CAGGTGAAGAATGCCTTTAATAAGCTC- 
CAAGAGAAAGC~ATCTACAAAGCCATGAGTGAGTTTGAC- 
A_q~-3' (28); and IFN-"/5'-TGACTAATTATICGGTAACTGACT- 
TGAATG-Y. 
RNA  Isolation and PCR Analysis.  Total RNA was isolated 
from PBMC or sorted cell populations by RNA isolation solvent 
(RNAzol B; TEbTEST, Inc., Friendswood,  Texas). The whole pro- 
cedure was performed as described for mouse cytokines (29, 30). 
cDNA was prepared in duplicate by reverse transcription using Su- 
perscript  (GIBCO-BRL,  Gaithersburg, ME)) according to  the 
specifications of the supplier. Each cDNA was amplified by PCK 
in the presence of  HPRT, a housekeeping enzyme, or lymphokine- 
specific primers. As reference, 11 twofold dihtions of a standard 
cDNA were included. The standard sample was cDNA obtained 
from ConA-activated CD4 + T ceil done B21. PCR amplification 
for cytokine-specific  primers was performed in 50/~1 with 1 U of 
Taq polymerase  (Perkin-Elmer  Corp., Emeryvilh, CA) by a 96-well 
thermocyder (GeneAmp PCK System 9600; Perkin-Elmer Corp.) 
under the following conditions: 30 cycles of 30 s at 94~  30 s 
at 55~  and 1 rain at 72~  Subsequently, 10/~1 of the ampli- 
fied product was dot-blotted  in duplicate to Nytran membrane 
(Schleicher & SchueU, Inc., Keene, NH) using a 96-well manifold 
(Bin-Red Laboratories, Richmond, CA). Oligonudeotide  probes 
specific for  a  sequence internal  to  the  primers used  in  the 
amplification, were 3zp eud-labeled and hybridized to the mem- 
branes. For quantification  of  the signal, the membranes  were scanned 
by a Phosforimager (Molecular Dynamics, Sunnyvale, CA). All 
sample values  were within the range of the reference curve. HPRT 
and cytokine mRNA values were determined based on the refer- 
ence titration curve. Calculations  were performed  using ELISA  soft- 
ware (Softmax; Molecular Devices, Inc., Menlo Park, CA). Values 
of each sample were expressed as ratio between the lymphokine 
value and the HPRT value using the following formula: 100x 
[(mean of cpm of PCR for cytokine/mean of cpm of PCR for 
HPKT)]. 
Immunofluorescence Analysis.  For detection of cell surface Ags, 
10  s cells were labeled with FITC or PE-conjugated mAbs. Cells 
were incubated for 30 rain with the appropriate mAb at 4~  in 
PBS with 0.1% BSA and 0.02 mM NAN,. After three washes, the 
labd cell samples were analyzed  on a FACScan  |  (Becton Dickinson 
& Co.). Where indicated, fluorescence  of the cells is expressed as 
channel number, on a logarithmic scale, representing mean fluores- 
cence intensity (MFI) of positive ceils. The MFI reflects the Ag 
density per cell. 
For cell sorting, PBMC were labeled according to the same pro- 
cedure in PBS with 5% FCS and sorted by FACStar  |  or Vantage 
(Becton Dickinson & Co.). The purity of sorted T cell, non-T cell, 
monocytes, and B ceil fractions  was >99.2%. The sorted cell popu- 
lations were immediately used for mKNA extraction. 
Determination of Lyraphokine Production.  Resting T cell clones 
were collected 8-10 d after activation with the feeder ceil mixture, 
washed, and stimulated with the host-derived or allogeneic EBV- 
LCL (1:1 ratio) or in the presence of Con A (10/~g/ml) or TPA 
(1 ng/ml) plus anti-CD3 mAb (0.1/~g/ml) or TPA (1 ng/ml) plus 
Ca  z§  ionophore (A23187, 500 ng/ml). Supernatants were har- 
vested after incubation for 24 h. For kinetics of  lymphokine produc- 
tion, supernatants were collected 1, 4, 8, 12, 36, 48, and 72 h after 
stimulation. The presence of Ib2 and IL-10 was quantified by im- 
munoenzymetric assays  performed as previously  described  (25). Sen- 
sitivity of  these assays  was 20 pg/mlfor Ib2, and 50 pg/ml for II:10. 
Results 
~-2 and 11.-10 Product~ by Host-reactive T Cell Clones.  We 
previously showed that donor-derived CD4 § T  cell clones, 
obtained from the PBMC of human chimeras, proliferate and 
produce normal amounts of IFN-~, in response to host ceils 
that are HLA incompatible (12). Here, we investigated the 
ability of host-reactive T cell dones isolated from patient RV, 
to produce IL-2 and IL-10 after activation by the EBV-LCL 
of host origin. In Fig. 1 A it is shown that 29 of the patient's 
CD4 + T cell clones produced very low levels of IL-2 (mean 
+_  SE  =  156  +  40 pg/ml) after Ag-specific stimulation. In 
contrast, IL-10 was produced at unusual high levels (15,719 
_+ 2,226 pg/ml). Both cytokines were undetectable in super- 
natants of unstimulated T  cell clones.  IL-10 production by 
the EBV-LCL used as stimulator ceils was in all cases <500 
pg/ml, whereas these cells, as expected, did not produce IL-2 
(data not shown). A similar pattern of high IL-10 (14,495 
+_ 906 pg/ml) and very low IL-2 production (179 _+ 61 pg/ml) 
was also observed,  when the T cell clones were activated by 
TPA plus anti-CD3 mAb (Fig. 1 C) which has been shown 
to induce optimal IL-10 synthesis (19). In contrast, activa- 
tion by Con A (Fig. 1 B) or TPA plus Ca  z  + ionophore (Fig. 
1 D) resulted in normal levels of IL-2 production by the host- 
reactive T  cell clones (756  ,+  194 and 6,697  _+  975 pg/ml 
respectively). However, IL-10 production was decreased after 
stimulation with Con A (2,462  _+ 593 pg/ml) and to a lesser 
extent after TPA plus Ca  2  + ionophore activation (11,624  ,+ 
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Figure  1.  IL-10 and  IL-2 production  by  host-reactive 
CD4 + T cell clones (e) of patient RV, after Ag-spedfic ac- 
tivation with the host EBV-LCL (A), polyclonal activation 
with Con A  (B),  TPA plus anti-CD3 mAb (C), and TPA 
plus Ca  2+ ionophore  (D). See Results for the mean values. 
3,779  pg/ml), both of which have been shown to be poor 
IL-10 inducers (19). 
The low levels of IL-2 in supernatants of Ag-activated host- 
reactive T cell clones were not due to IL-2 consumption  by 
the proliferating T  cell clones,  since addition of anti-IL-2 
receptor mAb did not result in increased IL-2 levels (data not 
shown). 
High IL-IO  Production Is Specific for Host-reactive T  Cell 
Clones.  To determine whether high IL-10 production in re- 
sponse to HLA Ags is a specific property of host-reactive T 
cell clones, we compared the amounts of IL-10 produced by 
the host-reactive T cell clones of patient RV with those of 
normal alloreactive CD4 + T cell clones isolated from PBMC 
of the patient  and from  PBMC  of a normal donor.  Four 
different aUogeneic HLA mismatched EBV-LCL were used 
as stimulator ceils. As shown in Table 1, both patient- and 
normal donor-derived,  alloreactive T  cell clones produced 
Table  1.  IL-IO Production after Antigen-specific Stimulation* of 
T Cell Clones Obtained  from a Human Chimera (RV) andJrom a 
Normal Donor (ND) 
IL-IO  (pg/ml) 
T  cell clones  No.  tested  Mean values  SE 
Hostreactive  (RV)  29  15,719  2,226 
Alloreactive (P.V)  23  6067*  881 
AUoreactive  (ND)  23  6,900s  1,734 
*  EBV-LCL  were used as stimulators. 
* p  =  0.005 determined by Student's t test analysis. 
s p  =  0.02 determined by Student's  t test  analysis. 
significantly lower levels of IL-10 compared to those produced 
by host-reactive T cell clones. This indicates that high IL-10 
production is a specific property of host-reactive T cell clones. 
The alloreactive CD4 + T cell clones of the normal donor 
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Figure  2.  Kinetics of IL-10 and IIt2 production by two host-reactive 
CD4 + T cell clones (RV-C65 and RV-C85) isohted from patient RV and 
two alloreactive CD4 + T cell clones (MT-B14 and MT-B59) isolated from 
a normal donor. The alloreactive T cell clones  selected as control were 
considered high IL-10 producers. For both sets of T cell clones, the super- 
natants were harvested at different times (1, 4, 8, 12, 24, 36, 48, and 72 h) 
after Ag-specific  activation. 
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whereas the alloreactive CD4 + T  cell dones from the pa- 
tient synthesized variable amounts of IL-2 (398 •  94 pg/ml), 
which overall were not significantly higher than those pro- 
duced by host-reactive T cell clones. This suggests that low 
IL-2 production may be a general property of donor-derived 
T calls, irrespective of whether they are host-reactive or specific 
for third-party HLA Ags. 
Kinetics of lL-2 and IL-IO Production by Host-reactive T Cell 
Clones.  The  kinetics  of IL-2  and  IL-10  production by 
CD4 + T  cell clones  are  different.  IL-2  is detectable very 
early in the supernatant of activated  T  cell clones,  with a 
peak of production generally occurring after 8-12 h, whereas 
IL-10 is synthesized late after stimulation: it starts to appear 
8 h after activation and reaches the highest levels 24-48 h 
later (17). The kinetics of IL-2 and IL-10 production by host- 
reactive CD4 + T cell clones and alloreactive T  cell clones, 
obtained from a normal donor, were investigated after stim- 
ulation by specific HLA antigens presented by EBV-LCL (Fig. 
2). To study the kinetics of IL-10 optimally, high IL-10-pro- 
ducing control alloreactive T cell clones were selected. The 
alloreactive T cell dones of the normal donor (MT-B14 and 
MT-B59) produced IL-10 at low levels within the first 12 h 
of culture. IL-10 increased progressively and reached peak 
values at 36-48 h after activation. Similar kinetics have been 
reported for Ag-specific CD4 + T cell dones (17). Interest- 
ingly, significant levels of IL-10 were already present in the 
supernatant of host-reactive T cell clones (RV-C65 and RV- 
C85) at 4 h after activation.  Thereafter, 1L-10 levels increased 
rapidly and the highest concentrations were obtained 12-24 h 
after activation. IL-2 production by the control CD4 + T cell 
dones showed normal kinetics, since considerable  levels of 
IL-2 could be detected 3 h after activation. In contrast, low 
levels of IL-2 started to be detected in the supernatants of 
host-reactive T  cell dones only 12 h after activation. In T 
cell done RV-C85, the highest concentrations of IL-2 were 
detectable between 12 and 24 h, and in T cell done RV-C65, 
between 36 and 48 h after activation. No differences were 
observed between the two sets of clones in the kinetics of 
production of other lymphokines, such as IFN-~, (data not 
shown). These results illustrate the specific kinetics of Ag- 
induced IL-2 and IL-10 synthesis by host-reactive T cell clones 
in which IL-2 production is preceded by that of IL-10. 
of  and E. 0go  s v-w o. 
ation.  IL-10 inhibits (allo)antigen-specific  T cell prolifera- 
tion in the presence of monocytes as APC (20, 22). To inves- 
tigate whether endogenous IL-10 production could contribute 
to the reduced proliferation of host-reactive T cell done~ their 
proliferative  responses were analyzed in the presence of different 
concentrations of anti-E-10 mAb. Alloreactive control T cell 
clones obtained from a healthy donor, were tested in parallel. 
For these experiments, monocytes expressing the relevant FILA 
Ag of the host were used as stimulators. In Table 2, it is shown 
that the antigen-specific proliferative responses of host-, but 
not of alloreactive T cell clones, were significantly (p *g0.005) 
increased in the presence of anti-IL-10 mAb (mean percen- 
tages of increase, 39, 50, and 57 for the three different con- 
centrations of mAb). This indicates that IL-10 produced by 
the host-reactive T cell clones suppresses proliferation of these 
cells in vitro. In addition, proliferation of the host-reactive 
T cell clones was further inhibited in the presence of exoge- 
nous IL-10 (Table 2). IL-10 inhibited the proliferative responses 
of the control CD4 + alloreactive T  cell clones to a similar 
extent (Table 2). 
Table  2.  Antigen-specific  Proliferative Responses of T  Cell Clones in the Presence of Anti-IL-lO mAb or of Exogenous IL-IO" 
Anti-IL-10  IL-10 
T call clones  Medium  0.05/zg/ml  0.5 Izg/ml  5/~g/ml  1 U/ml  10 U/ml  100 U/m1 
Host-reactive 
RV-B  11  11.9  •  1.1'  18.9  _+  0,9  19.1  •  0.8  21.2  •  1.9  6.2  •  0.8  1.4  •  0.2  1.3  •  0.2 
RV-C  15  4.8  •  0.2  6.0  +  0.3  5.8  +  0.2  6.1  •  0.3  2.9  •  0.4  1.0  _+  0.1  0.6  •  0.0 
RV-C  30  15.5  -+  0.1  19.9  •  0.1  22.0  +-  1.1  20.7  •  0.9  15.7  •  0,7  8.3  +  0.2  4.2  •  0.5 
RV-C  65  5.9  •  0.1  10.1  +  0.1  11.4  -+  0.4  11.8  +  0.7  5.0  +  0,7  1.9  •  0.1  1.2  _+  0.2 
RV-C  85  5.1  _+  0.3  5.8  •  0.7  6.7  •  0.1  7.4  •  0.5  3.3  •  0.3  0.9  •  0.1  0.4  _+  0.0 
Alloreactive 
MT-B  13  149,9  •  7.0  120.4  •  6.3  131.2  •  24.4  138.2  _+  15.2  117.1  •  25.0  53.9  •  3.0  52.2  _+  4.0 
MT-B  46  72.6  _+  2.8  70,2  _+  2.3  68.6  •  0.2  68.6  •  0.4  51.3  •  1.6  33.3  •  1.4  30.8  _+  1.1 
MT-B  49  98.2  •  2.9  91.9  •  9.2  86.7  •  9.6  80.0  •  2.9  68.9  •  7,0  35.2  •  1.0  30.8  •  1,4 
MT-B  51  171.4  •  13.4  167.2  _+  19.4  168.7  •  17.4  179.9  •  23.7  163.1  •  2.0  109.6  •  9.1  103.8  •  10.6 
MT-B  59  83.1  _+  6.1  86.4  •  2.4  89.9  +  3.8  85.3  •  2.3  54.8  •  7.8  21.4  •  1.9  18.0  •  1.9 
*  Monocytes expressing the relevant HLA antigens were used as stimulators. 
* [3H]TdR incorporation cpm  x  10 -3  _+ SD. 
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Figure 3.  PCR determination of IL-10 (.4), IL-2 (B), and IFN-3' (C) 
mRNA expression in patient's (RV) and normal donors' (ND) total PBMC 
and sorted T and non-T cell populations. Values are expressed as the ratio 
between the lymphokine and HPRT (see Materials and Methods). Values 
referred to the patient are representative  of results obtained from three 
different experiments performed on three PBMC samples; data referred 
to ND represent the mean values obtained from five subjects (+ SD). (*) 
A value that differs from the mean value ofND  •  2 SD and that is consid- 
ered statistically significant. 
Expression of lL-lO mRNA In  Viv~  Since  host-reactive 
T cells are present at high frequencies in the PBMC of pa- 
tient RV (12), we hypothesized that IL-10, which is strongly 
produced by Ag activated host-reactive T cells in vitro, should 
be detectable in vivo, where donor-derived,  host-reactive T 
cells continuously and specifically  interact with the host ceils. 
Therefore, IL-10 mRNA expression in the patient's PBMC 
was determined by using a semiquantitative  PCR analysis. 
IL-10, IL-2, and IFN-3' mRNA levels of the patient's PBMC 
were compared with those of normal donors in the absence 
of activation.  The results shown in Fig. 3 A  indicate that 
IL-10 mRNA expression in the PBMC of patient RV was 
significantly higher than the mean levels of IL-10 mRNA 
present in the PBMC of  five normal donors tested in parallel. 
PCR  analysis of sorted  CD3 +  T  ceUs and  non-T  cells 
(CD14+CD16+CD20 ~') showed that IL-10 mRNA expres- 
sion in both fractions was significantly higher in the patient 
than in the normal donors. A remarkable high IL-10 mRNA 
expression was detected in the non-T cell subset. PCK data 
obtained  from purified  CD14 + monocytes and CD20 § B 
cells showed that IL-10 mRNA is mainly expressed  by mono- 
cytes, whereas B cells were negative, or expressed very low 
levels of IL-10 mRNA. In addition,  IL-10 mRNA expres- 
sion  in  the  patient's  monocytes was  much  higher  (IL- 
10/HPRT ratio, 8.5) than in that of the normal donors (IL- 
10/HPRT ratio, 0.8 •  0.3). IL-2  mRNA (Fig. 3 B) in PBMC 
and in T cells of patient KV was decreased compared to that 
of normal donors, although this decrease  was more significant 
in total PBMC than in the sorted T cell subset. IL-2 mRNA 
was not detectable in non-T cell subsets. IFN-3, mRNA ex- 
pression (Fig. 3 C) in the PBMC and in T cells of the patient 
and of normal donors were comparable. In contrast,  the ex- 
pression of IFN-? mRNA was low in the non-T cells of the 
patient. This is in line with the observation that the amount 
of IFN-3, present in the non-T cell subset seems to be related 
to the proportion of CD16 + cells (Bacchetta, R., et al., un- 
published data), which was very low (<4%) in the patient 
as compared to the normal donors (4-10%). Thus in patient 
RV, IL-10 is highly expressed in vivo by both donor-derived 
T ceils and host-derived monocytes. This is consistent with 
the observation that spontaneous IL-10 production in vitro 
by the patient's PBMC was also high, median, 3,214 pg/ml, 
vs. the 518 pg/ml previously observed in a series of normal 
donors (25), despite the fact that the percentages of CD3 + 
T  cells, CD20 + B cells, and CD14 + monocytes in the pa- 
tient's PBMC were comparable to those of healthy donors. 
To investigate whether high levels of IL-10 production in 
vivo are a general phenomenon in SCID patients  after al- 
logeneic stem call transplantation,  we measured the IL-10 
mKNA expression in seven other SCID patients with split 
chimerism.  Three were reconstituted with fully HLA mis- 
matched FLT and four with haploidentical BMT. In all pa- 
tients,  immunotolerauce was achieved with stable engraft- 
ment of T cells derived from the donor, and B cells/monocytes 
of host origin. Results shown in Fig. 4 indicate that IL-10 
mRNA expression was significantly higher in the PBMC of 
patients compared to 13 normal donors tested (p  =  0.006). 
The higher IL-10 expression was present in both the donor- 
derived T cells (s <0.001) and the host-derived non-T cells 
(p  =  0.001). No remarkable differences were observed be- 
tween patients transplanted with FLT or BMT. These results 
demonstrate that high levels of IL-10 are consistently present 
in chimeric patients after allogeneic stem cell transplantation. 
Reduced HLA-DR Expression on Monocytes In Vivc,  IL-10 
dowuregnlates constitutive and IL-4- or IFN-y-induced  class 
II  HLA expression on APC in vitro  (20). To determine 
whether high endogenous IL-10 production would also re- 
sult in a reduced expression of class II HLA antigens in vivo, 
monocytes of patient RV were analyzed. Indeed, the MFI 
of HLA-DR expression on CD14 + monocytes freshly iso- 
lated from the patient was lower than that of monocytes of 
normal donors (Fig. 5). In addition,  the reduced HLA-DR 
expression on the patient's monocytes did not change when 
these ceUs were incubated in medium for 48 h. In contrast, 
HLA-DR expression on control monocytes from healthy 
donors further increased twofold after this culture period. 
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and sorted T and non-T cell populations of SCID patients transplanted 
with haploidentical  BMT (VR, TJ, DE, NJL) or fully  I-ILA  mismatched 
FLT (TD, MJ, SP), and of 13 normal  donors (ND). Values are expressed 
as the ratio between  IL-10 and HPKT (see Materials  and Methods). (NT) 
Not tested. Statistical  analysis  was performed  by unpaired  Student's t test; 
p values  between  patients  and normal  donors  were the following:  PBMC, 
/, = 0.006; T cells, p <0.001; non-T cells,  f  -  0.001. 
HLA-DR expression  doubled when both the patient's and 
control monocytes were incubated in the presence  of anti- 
IL-10 mAb, but HLA-DK expression on the patient's mono- 
cytes never reached the level of that of the normal donors' 
TIME 0  48 h  48 h 
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Figure  5.  MFI of HLA-DR  expression  on CD14  + monocytes  of pa- 
tient RV and of normal donors (ND). One representative  experiment  out 
of three performed  is shown. The phenotype  was done  on freshly  isohted 
PBMC (TIME 0) and after  48 h of incubation  in medium  or in medium 
+ anti-IL-10  mAb (5 #g/m1). (Control)  Cells stained  with isotypic  control 
mAbs. 
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Figure 6.  Proliferative  responses of T cells isohted from two normal 
donors (ND A and ND B) toward sorted CD14  + monocytes  of patient 
RV and of two normal donors (NDI and ND2), in the absence (J) or 
in the presence (Ill) of anti-IL-10  mAb (20 #g/ml). Values are expressed 
as cpm x 10 .3 and represent the mean pH]TdR incorporation  of tripli- 
cate cultures + SD. Background  cpm of cells cultured in medium alone 
were subtracted. 
monocytes. No difference in the HLA-DR expression  on B 
cells was observed between patient RV and normal donors 
tither freshly isolated or after 48 h of  culture (data not shown). 
Stimulatory Capacity of the Patient's Monocytes.  The IL-IO- 
induced downregulation ofdass II HLA expression on mono- 
cytes has been associated with their reduced capacity to present 
Ag and to induce Ag-specific T cell proliferation in vitro (20). 
Therefore, the Ag-presenting capacity of the monocytes of 
patient KV was investigated. In Fig. 6 it is shown that, al- 
though the proliferative responses  of T  cells from normal 
donors toward the patient's sorted CD14 + monocytes are 
somewhat lower than those toward the two controls' sorted 
CD14 + monocytes, they are within the normal range.  In 
addition, the proliferative responses  were not significantly 
increased in the presence  of neutralizing concentrations of 
anti-IL-10 mAb. These results indicate that under the present 
culture conditions, the overall stimulatory capacity of the pa- 
tient's monocytes was not impaired when normal T cells were 
used as responders.  In addition, no inhibitory effect of en- 
dogenous IL-10 was observed, suggesting that this effect could 
be overcome by the relatively high levels of IL-2 produced 
by normal T  cells during allogeneic responses. 
Discussion 
Transplantation of HLA mismatched hematopoietic stem 
calls in patients suffering from SCID may result in a sdective 
T lymphocyte  chimerism (5, 8). In these split human chimeras, 
immunologic reconstitution can be achieved with tolerance 
between donor and host cells. The lack of in vivo GVHD 
and the in vitro unresponsiveness  to the host cells in primary 
MLCs, indicate that donor-derived T  lymphocytes develop 
tolerance to HLA antigens uniquely expressed on recipient 
ceils (12, 31, 32). This tolerance is-not entirely due to donal 
deletion, since host-reactive T  cells can be isolated at high 
frequencies from the peripheral blood of SCID patients recon- 
stituted either with fully mismatched fetal liver stem calls 
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et al., manuscript in preparation).  Therefore, a peripheral an- 
toregulatory mechanism should be responsible for the in vivo 
homeostasis. 
In this study, we demonstrate that donor-derived CD4 + 
host-reactive T cell clones, isolated from one of such a human 
chimeras,  produced unusually high amounts of IL-10 after 
Ag-spedfic activation. This property is unique for host-reactive 
T cell clones, since control aUoreactive T cell clones, isolated 
from both the patient and normal donors, produced normal 
levels of IL-10 (19). Host-reactive T call clones also have dis- 
tinct kinetics of IL-10 secretion which can be detected in the 
supematants at high concentrations very early after Ag acti- 
vation, whereas normally IL-10 is produced late after stimu- 
htion (17). In addition, the Ag-specific proliferative responses 
of the host-reactive T call dories, unlike those of alloreactive 
T  cell clones isolated from normal donors, were increased 
in the presence of anti-IL-10  mAb, indicating that the en- 
dogenous IL-10 production plays a role in suppressing the 
proliferation of these cells. In contrast, CD4 + host-reactive 
T cell clones produced very low amounts of IL-2, especially 
after specific activation with Ag or with TPA plus anti-CD3 
mAb.  However,  the  host-reactive  T  cell clones produced 
normal levels of IL-2 after polyclonal activation by Con A 
or TPA plus Ca  2  + ionophore, indicating that low IL-2 pro- 
duction is not an intrinsic property of these calls, but occurs 
only after Ag-specific or TCR-mediated stimulation. Indeed, 
the alloreactive T cell clones isolated from the same patient, 
also produced low levels of IL-2 after Ag-specific activation, 
suggesting that low IL-2 production may not be a specific 
property of host-reactive T cell clones. IFN-3, production by 
the host-reactive T cell clones was comparable to that of al- 
loreactive T cell clones, independently of their mode of acti- 
vation (12). 
In line with the observations at the clonal level, we found 
higher levels of IL-10 mRNA expressed in the patient's PBMC 
than in those of normal donors. Separation of the PBMC 
in purified T and non-T cell populations indicated that both 
cell fractions expressed high levels of IL-10 mRNA, although 
IL-10 mRNA was considerably more enhanced in the non-T 
cell compartment. Purified B cells expressed no, or low levels 
of IL-10 mKNA, whereas high expression of IL-10 mKNA 
was detected in the monocytes of the patient. IL-2 mRNA 
expression  was much lower in the patient than in normal 
donors, which is compatible with the results obtained with 
both host- and aUo-reactive T cell clones, and suggests that 
low IL-2 production may be a general characteristic  of the 
patient's T cell compartment. IFN-3, mKNA expression in 
the patient was comparable to that of normal donors, with 
the exception that non-T cells of patient had low levels of 
IFN-3, mRNA, which was probably due to the very low 
proportion of NK cells present in the patient (12). 
Interestingly, high endogenous IL-10 production was not 
restricted to patient RV, but was observed in seven other 
chimeras,  three of whom had been transplanted with fetal 
liver cells and four with haploidentical bone marrow cells. 
Also in these patients, high levels of IL-10 mRNA expres- 
sion were present in the donor-derived T and in the non-T 
cell fractions which remained of host origin after transplan- 
tation. 
Collectively, these data show a dear distinctive pattern in 
both kinetics and levels of in vivo and in vitro IL-10 and IL-2 
production in a human chimera and demonstrates that the 
high endogenous IL-10 production suppresses the activity 
of the host-reactive T ceils in vitro. In addition, they indicate 
that high endogenous IL-10 production is a general pheno- 
menon occurring in SCID patients successfully transplanted 
with HLA mismatched stem cells and in whom tolerance 
is achieved. 
IL-10 has multiple suppressive effects on various effector 
phases of the immune response (16, 17). In humans, IL-10 
was found to prevent Ag-specific proliferative T-cell responses 
by reducing the antigen-presenting capacity of APCs that 
were associated with downregnlation of class II MHC on 
these cells (20).  IL-10 also inhibited the synthesis of most 
monokines (18). Furthermore, IL-10 has a direct inhibitory 
effect on T cell proliferation by specifically downregnlating 
IL-2 mKNA expression and IL-2 production by PBMC, T 
cells, and T cell clones belonging to different Th subsets (21). 
We recently described  that exogenous IL-10 also acts as a 
potent inhibitory factor for cytotoxic and proliferative  al- 
loresponses in a one-way primary MLC. In addition, the pres- 
ence of anti-IL-10  mAb enhances the alloreactive prolifera- 
tive responses, indicating that endogenous IL-10 production 
modulates allogeneic responses  in MLCs (22). 
Based on these biological activities,  we hypothesize that 
the endogenous IL-10 production in our transplanted patients 
is responsible  for maintaining tolerance in vivo. IL-10 may 
inhibit the development of GVHD by preventing optimal 
activation and IL-2 synthesis by host-reactive  T cells. In ad- 
dition, it may suppress the antigen-presenting capacity and 
cytokine production by host calls. Several studies in mice (33, 
34) and human (35, 36) indicate that cytokines play a major 
role in acute GVHD, not only by facilitating T  cell expan- 
sion but also by directly causing tissue damage. High serum 
levels of IL-2, IFN-3,, IL-1, and TNF-ol have been correlated 
with the severity of acute GVHD, and administration of Abs 
which block the effects of these cytokines can prevent and/or 
arrest GVHD (37). On the other hand, altered IL-2 induc- 
tion pathways have been reported to be responsible for the 
acquisition of peripheral anergy (14, 15, 38, 39). 
The signals which trigger IL-10 production in transphnted 
SCID patients remain to be identified. However,  resting T 
cells and monocytes do not produce IL-10, which requires 
activation of these cells (19). This implies that high IL-10 
production in vivo reflects a chronic activation of donor T 
cells and host monocytes because of ongoing immune response. 
One could envisage that the continuous interactions between 
host-reactive  T  cells and host HLA antigens presented by 
monocytes in vivo result in mutual activation of these cells 
and the rapid production of high levels of IL-10 locally. These 
high local levels of IL-10 prevent the host-reactive T  cells 
to proliferate  and produce IL-2, whereas,  in an autoregula- 
tory fashion, they simultaneously inhibit the production of 
proinfl~rnmatory cytokines by the monocytes and reduce class 
II HLA expression on these cells, thereby modifying their 
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presenting capacity of the monocytes results in a particularly 
aberrant mode of T cell activation which contributes to the 
high IL-IO production by the host-reactive T cells, remains 
to be determined. 
In the proposed model, endogenous IL-10 acts mainly lo- 
cally as an antigen-specific suppressor factor which inhibits 
activation and proliferation of donor-derived T cells able to 
recognize the HLA antigens of the host. This notion is sup- 
ported by the observation that no significant levels of cir- 
culating IL-10 could be detected in these patients. However, 
we have indirect evidence that endogenous IL-10 also may 
have systemic effects on cells of the immune system in pa- 
tient RV, as is illustrated by the low IL-2 mRNA expression 
in all T  cells,  the reduced IL-2 synthesis by alloreactive T 
cell clones, and the reduction of class II HLA expression on 
circulating monocytes. This reduced class II HLA expression 
could be partially restored after in vitro incubation of the 
monocytes in the presence of anti-IL-10 mAb, indicating that 
IL-10, which has been shown to downregulate constitutive 
class II HLA expression on monocytes in vitro, is probably 
also responsible for the dowrtregulation of these antigens in 
vivo. Preliminary in vitro experiments have shown that mono- 
cytes pretreated with IL-10 remain refractory for induction 
of class II HLA antigens by IFN-3' and IL-4 for extended 
periods (de Waal Malefyt, R.,  unpublished observations). 
Therefore, although endogenous IL-10 production may have 
its strongest impact locally on host-reactive T cells, weaker 
systemic effects on all T cells and monocytes probably occur 
concomitantly. When this scenario is correct, it predicts that 
these patients are constantly in a state of mild "natural" im- 
munosuppression. 
Several observations are against this hypothesis. First, all 
patients are apparently in good health. In addition, their pe- 
ripheral blood T  cells were found to respond normally to 
allogeneic stimulations in primary MLCs (12) or to exoge- 
nous antigens such as tetanus toxoid (Roncarolo, M.-G., un- 
published observation). These results suggest that, despite 
the fact that alloreactive T cell clones of patient RV produced 
low levels of IL-2, donor T cells overall produce enough IL-2 
in vivo to guarantee normal immune responses.  In fact it has 
been reported that T  cell dones in general produce 10-fold 
less IL-2 than fleshly isolated T  cells after activation (18). 
Furthermore, the monocytes of patient RV, despite their re- 
duced dass II HLA expression, induced proliferative responses 
of T  cells of normal donors that were somewhat lower to 
those obtained with  control monocytes, but  which were 
definitely within the normal range. Moreover, under these 
culture conditions, anti-IL-10 mAb did not significantly en- 
hance the proliferative responses of the normal T cells, sug- 
gesting that normal levels of IL-2 production by these cells 
can overcome the suppressive effects of IL-10 in vitro. These 
findings further support the notion that sufficient levels of 
IL-2 produced in vivo by the donor T cells, after activation 
with infectious agents, such as bacteria or viruses, can coun- 
teract the suppressive  effects of IL-10, which allow normal 
immunoprotection without breaking the state of tolerance 
that would be mainly controlled locally by IL-10. 
Collectively, our data provide a new insight in the impor- 
tance of IL-10 produced in vivo by accessory cells and T cells 
for induction and maintenance of tolerance after allogeneic 
stem cell transplantation. In addition, they indicate that IL-10 
may have potential clinical utility in preventing or reducing 
GVHD and allograft rejection. 
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